NM_002693.2(POLG):c.3463A>G (p.Ile1155Val) AND Progressive sclerosing poliodystrophy

Clinical significance:Uncertain significance (Last evaluated: Nov 21, 2017)

Review status:1 star out of maximum of 4 stars

criteria provided, single submitter

Based on:
1 submission [Details]
Record status:

Allele description [Variation Report for NM_002693.2(POLG):c.3463A>G (p.Ile1155Val)]

NM_002693.2(POLG):c.3463A>G (p.Ile1155Val)

POLG:DNA polymerase gamma, catalytic subunit [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
Genomic location:
Preferred name:
NM_002693.2(POLG):c.3463A>G (p.Ile1155Val)
  • NC_000015.10:g.89318560T>C
  • NG_008218.2:g.21236A>G
  • NM_002693.2:c.3463A>G
  • NP_002684.1:p.Ile1155Val
  • LRG_765t1:c.3463A>G
  • LRG_765:g.21236A>G
  • LRG_765p1:p.Ile1155Val
  • NC_000015.9:g.89861791T>C
Protein change:
dbSNP: rs749640920
NCBI 1000 Genomes Browser:
Molecular consequence:
  • NM_002693.2:c.3463A>G - missense variant - [Sequence Ontology: SO:0001583]


Progressive sclerosing poliodystrophy (MTDPS4A)
Alpers Syndrome; Mitochondrial DNA depletion syndrome 4A (Alpers type); Alpers-Huttenlocher Syndrome
MedGen: C0205710; Orphanet: 726; OMIM: 203700

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
SCV000754791Invitaecriteria provided, single submitter
Uncertain significance
(Nov 21, 2017)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing



Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11.

PubMed [citation]

Details of each submission

From Invitae, SCV000754791.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)


This sequence change replaces isoleucine with valine at codon 1155 of the POLG protein (p.Ile1155Val). The isoleucine residue is highly conserved and there is a small physicochemical difference between isoleucine and valine. This variant is present in population databases (rs749640920, ExAC 0.02%). This variant has not been reported in the literature in individuals with POLG-related disease. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The valine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Mar 30, 2019

Support Center